论文部分内容阅读
目的:观察中药联合加巴喷丁治疗原发性三叉神经痛的临床疗效,指导临床治疗及用药。方法:220例原发性三叉神经痛患者随机分为观察组与对照组,每组各110例,观察组采用口服中药+加巴喷丁治疗,对照组采用加巴喷丁治疗,两组均治疗4周后,评价患者临床疗效,对比两组患者治疗前后VAS(视觉模拟评分)及PSQI(匹兹堡睡眠质量问卷)评分变化情况,并记录与治疗及用药相关的不良反应发生情况。结果:治疗后,观察组患者的总有效率为89.09%,高于对照组的75.45%,差异具有统计学意义(P<0.05)。治疗后,两组患者VAS及PSQI评分水平均低于治疗前,其中观察组患者VAS及PSQI评分低于对照组,差异具有统计学意义(P<0.05)。两组患者不良反应发生率相当,不具有统计学差异(P>0.05)。结论:口服中药配合巴喷丁治疗原发性三叉神经痛临床疗效却轻,能够改善患者的睡眠质量,且安全性较好,值得临床推广使用。
Objective: To observe the clinical efficacy of traditional Chinese medicine combined with gabapentin in the treatment of primary trigeminal neuralgia, to guide clinical treatment and medication. Methods: 220 patients with primary trigeminal neuralgia were randomly divided into observation group and control group, 110 cases in each group. The observation group was treated with oral Chinese medicine + gabapentin, while the control group was treated with gabapentin. After both groups were treated for 4 weeks, The clinical efficacy of the two groups were compared before and after treatment VAS (visual analog scale) and PSQI (Pittsburgh Sleep Quality Questionnaire) score changes, and record the treatment and medication-related adverse reactions. Results: After treatment, the total effective rate of the observation group was 89.09%, which was higher than that of the control group (75.45%), the difference was statistically significant (P <0.05). After treatment, the scores of VAS and PSQI in both groups were lower than those before treatment, in which the VAS and PSQI scores of the observation group were lower than those of the control group, the difference was statistically significant (P <0.05). The incidence of adverse reactions in both groups was similar, with no statistical difference (P> 0.05). Conclusion: Oral Chinese medicine combined with gabapentin in the treatment of primary trigeminal neuralgia is light, can improve the quality of sleep in patients with good safety and is worthy of clinical promotion.